NeoRad is a prospective, randomized, international multicenter phase III trial comparing preoperative versus postoperative radiotherapy following neoadjuvant chemotherapy in high-risk breast cancer. The primary objective is to evaluate whether preoperative radiotherapy improves disease-free survival (DFS) and reduces radiation-induced late toxicity. Eligible patients are adult women with histologically confirmed unilateral invasive breast cancer requiring neoadjuvant chemotherapy and radiotherapy. Hormone receptor and HER2 status are unrestricted; patients with grade G1–G3 tumors and ECOG performance status =2 are eligible. Participants are randomized to receive either preoperative or postoperative radiotherapy. Key secondary endpoints include radiation-associated late effects and additional long-term clinical outcomes.
NeoRad is an international clinical trial for women with breast cancer at higher risk of recurrence. The study investigates whether radiotherapy given before surgery is more effective than the standard approach of radiotherapy after surgery in patients who have already received chemotherapy before surgery. The aim of the trial is to determine whether the disease can be controlled for a longer time and whether late side effects from radiotherapy can be reduced. Adult women with unilateral invasive breast cancer who require neoadjuvant chemotherapy and radiotherapy may participate. Participants are randomly assigned to receive radiotherapy either before or after surgery. The study also evaluates treatment tolerability and long-term outcomes.
